Clinical Trial Aims to Unlock the Origins of Lung Cancer WASHINGTON and BOSTON, April 17, 2024 – In a promising step forward, GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), [...]
GO2 for Lung Cancer announced that researchers have described a new familial syndrome in people with lung cancer caused by an inherited gene mutation. The research study was published this month in the Journal of Clinical Oncology. The report chronicles [...]
Author: Jennifer C. King, PhD, Chief Scientific Officer GO2 for Lung Cancer has launched the SPARK Study to help understand cancer driven by changes in the KRAS gene. This study is through our medical research consortium, ALCMI (Addario Lung [...]
SAN CARLOS, Calif., (November 30, 2022) – The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, has launched the SPARK Study to help researchers better understand treatment resistance in patients with KRAS-positive lung cancer and [...]
A groundbreaking new survey, conducted by a multi-disciplinary team in GO2 for Lung Cancer’s Lung Cancer Registry, found that sexual dysfunction is prevalent in women with lung cancer. The results were shared by study lead Dr. Narjust Florez (Duma) with [...]